Key facts
- This page summarizes Dr. Stephen LaMond's Form 4 filing for Peak Bio, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Sep 2023, 16:05.
Dr. Stephen LaMond - 26 Sep 2023 Form 4 Insider Report for Peak Bio, Inc.
- Reporting relationship
- Interim Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 26 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Sep 2023, 16:05:23 UTC
- Prior SEC filing
- 28 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dr. Stephen LaMond
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dr. Stephen LaMond filed Form 4 for Peak Bio, Inc. on 28 Sep 2023.
Change
- Previous filing in this sequence was filed on 28 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PKBO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +3,000
- Change %
- +21%
- Price
- Shares after
- 17,250
- Date
- 26 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
PKBO
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +2,600
- Change %
- +15%
- Price
- Shares after
- 19,850
- Date
- 27 Sep 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On September 26, 2023, Dr. Stephen LaMond purchased a total of 3,000 shares of the Company's Common Stock at prices ranging from $0.13 per share to $0.14 per share.
Footnote F2
On September 27, 2023, Dr. Stephen LaMond purchased a total of 2,600 shares of the Company's Common Stock at prices ranging from $0.13 per share to $0.14 per share.
SEC remarks
Interim Chief Executive Officer